GILD/AMRN: What do you think of Amarin as a potential acquisition for GILD?
In addition to the November presentation slides of Amarin I posted earlier today, see the other links I have under "my stocks" in my profile above.
Zumantu updates the potential indications almost daily on the Amarin board.
Sam reports scrip growth nearly every week[Friday is typical], most of which growth which must be off-label so far..
We hold many 1000s of shares of both GILD and AMRN. Both are currently very profitable as investments on current $$ basis.
Listening to the GILD qtr CC, AMRN provides the potential needed technology platform that GILD is looking for, per CSO Norbert B. and CEO Milligan. Anti-inflammatory MOA---> CVD prevention/therapy, even oncology support.
And the capsule containing 96% icosapent ethyl[EPA], well IP-protected, is certainly affordable---my own health insurance has left me with a small monthly co-pay on an off-label prescription of Vascepa since April 2013.
My DES disappeared within days of 1st dosage of V in April 2013.
Market Data 
Markets 
AI
